Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.73 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.70 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | DTYMK | P23919 | 2/20 | 0.66 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.65 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044161 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL29350133 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL3030614 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL29702495 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL18785117 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL78250 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL889289 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL703733 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL31211719 | 0.99 | POLB (0.81) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL2508784 | 0.99 | POLB (0.81) | POLBP2RY1ENPP1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180180567-A1 | MICROWELL ELECTRODE AND METHOD FOR ANALYSIS OF A CHEMICAL SUBSTANCE | BGI SHENZHEN (CN) | 2018-06-28 | — | — | US | disclosed |
| US-20180180567-A1 | MICROWELL ELECTRODE AND METHOD FOR ANALYSIS OF A CHEMICAL SUBSTANCE | BGI SHENZHEN (CN) | 2018-06-28 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-9688980-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION (DK) | 2017-06-27 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20150315567-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2015-11-05 | — | — | US | disclosed |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8932992-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-7727713-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2010-06-01 | — | — | US | disclosed |
| US-20070172869-A1 | Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | RNGTT, PPA1, PNP | POLB 13/4885P2RY1 258/4885ENPP1 16/4885 |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | IGFBP1, IGFBP5, IGF2BP1 | POLB 3895/4885P2RY1 2607/4885ENPP1 1976/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | POLB 3337/4885P2RY1 947/4885ENPP1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.